Curr Infect Dis Rep. 2010 Mar;12(2):147-54. doi: 10.1007/s11908-010-0092-5. Epub 2010 Mar 26.
The human herpesvirus 8 (HHV-8) is the oncogenic virus associated with Kaposi's sarcoma (KS) and lymphoproliferative disorders, namely, primary effusion lymphoma and multicentric Castleman's disease. KS is among the most common malignancies seen in HIV-infected patients despite the decreased incidence of KS in the era of highly active antiretroviral therapy. Advances in molecular pathology reveal HHV-8 tumorigenesis is mediated through molecular mimicry wherein viral-encoded proteins can activate several cellular signaling cascades while evading immune surveillance. This knowledge has led to the evolution of multiple therapeutic strategies against specific molecular targets. Many such therapeutic modalities have shown activity, but none have proven to be curative. Identifying possible prognostic factors is another active area of research. This review summarizes the recent developments in the fields of virus transmission, molecular biology, and treatment of HHV-8-related neoplasms.
人类疱疹病毒 8 型(HHV-8)是与卡波西肉瘤(KS)和淋巴组织增生性疾病相关的致癌病毒,包括原发性渗出性淋巴瘤和多中心卡斯特曼病。尽管在高效抗逆转录病毒治疗时代,KS 的发病率有所下降,但 KS 仍是 HIV 感染患者中最常见的恶性肿瘤之一。分子病理学的进展揭示了 HHV-8 的肿瘤发生是通过分子模拟介导的,其中病毒编码的蛋白可以激活几个细胞信号级联反应,同时逃避免疫监视。这一认识导致了针对特定分子靶点的多种治疗策略的发展。许多这样的治疗方法已经显示出活性,但没有一种方法被证明是治愈性的。确定可能的预后因素是另一个活跃的研究领域。本文综述了 HHV-8 相关肿瘤的病毒传播、分子生物学和治疗领域的最新进展。